Alpha 1-antitrypsin variants produced by recombinant DNA: differences in elastase inhibitory activity and resistance to oxidant agents. 1990

M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
Istituto di Tisiologia e Malattie dell' Apparato Respiratorio, IRCCS Policlinico San Matteo, Pavia, Italy.

Inherited or "acquired" deficiency of alpha 1-antitrypsin (believed to be the cause of pulmonary emphysema) will probably be treated in the future by replacement with alpha 1-antitrypsin purified from human plasma or produced by recombinant DNA, which seems promising because it permits site-specific mutagenesis in the oxidizable active site of the normal human alpha 1-antitrypsin. The aim of this in-vitro study was to investigate the elastase inhibitory activity and the resistance to oxidizing agents of normal human alpha 1-antitrypsin, a recombinant yeast-produced variant (VAL 358) and a recombinant E. coli-produced variant (LEU 358). The inhibitors were exposed to chemical oxidants (NCS, H2O2, xanthine/xanthine oxidase, chloramine-T) and to PMA-activated neutrophils. The elastase inhibitory activity was assayed on porcine pancreatic elastase and neutrophil elastase. Normal alpha 1-antitrypsin and VAL 358 variant were good inhibitors of both elastases. LEU 358 variant was the best inhibitor for neutrophil elastase, but it poorly inhibited the porcine pancreatic elastase. Normal alpha 1-antitrypsin was affected by all oxidants; both variants were almost totally resistant to chemical oxidants and to activated neutrophils. We conclude that recombinant alpha 1-antitrypsin variants differ in their elastase inhibitory activity and offer increased resistance to oxidant agents.

UI MeSH Term Description Entries
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D002700 Chloramines Inorganic derivatives of ammonia by substitution of one or more hydrogen atoms with chlorine atoms or organic compounds with the general formulas R2NCl and RNCl2 (where R is an organic group). Chloroamines
D004274 DNA, Recombinant Biologically active DNA which has been formed by the in vitro joining of segments of DNA from different sources. It includes the recombination joint or edge of a heteroduplex region where two recombining DNA molecules are connected. Genes, Spliced,Recombinant DNA,Spliced Gene,Recombinant DNA Research,Recombination Joint,DNA Research, Recombinant,Gene, Spliced,Joint, Recombination,Research, Recombinant DNA,Spliced Genes
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006861 Hydrogen Peroxide A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. Hydrogen Peroxide (H2O2),Hydroperoxide,Oxydol,Perhydrol,Superoxol,Peroxide, Hydrogen
D000515 alpha 1-Antitrypsin Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES. Trypsin Inhibitor, alpha 1-Antitrypsin,alpha 1-Protease Inhibitor,alpha 1-Proteinase Inhibitor,A1PI,Prolastin,Serpin A1,Zemaira,alpha 1 Antiprotease,alpha 1-Antiproteinase,1-Antiproteinase, alpha,Antiprotease, alpha 1,Inhibitor, alpha 1-Protease,Inhibitor, alpha 1-Proteinase,Trypsin Inhibitor, alpha 1 Antitrypsin,alpha 1 Antiproteinase,alpha 1 Antitrypsin,alpha 1 Protease Inhibitor,alpha 1 Proteinase Inhibitor
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014644 Genetic Variation Genotypic differences observed among individuals in a population. Genetic Diversity,Variation, Genetic,Diversity, Genetic,Diversities, Genetic,Genetic Diversities,Genetic Variations,Variations, Genetic
D014969 Xanthine Oxidase An iron-molybdenum flavoprotein containing FLAVIN-ADENINE DINUCLEOTIDE that oxidizes hypoxanthine, some other purines and pterins, and aldehydes. Deficiency of the enzyme, an autosomal recessive trait, causes xanthinuria. Hypoxanthine Oxidase,Hypoxanthine Dehydrogenase,Hypoxanthine-Xanthine Oxidase,Purine-Xanthine Oxidase,Dehydrogenase, Hypoxanthine,Hypoxanthine Xanthine Oxidase,Oxidase, Hypoxanthine,Oxidase, Hypoxanthine-Xanthine,Oxidase, Purine-Xanthine,Oxidase, Xanthine,Purine Xanthine Oxidase

Related Publications

M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
October 1989, The Journal of clinical investigation,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
April 1996, Journal of comparative pathology,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
August 1985, Biochemical and biophysical research communications,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
January 1988, Clinical chemistry,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
February 1989, European journal of clinical investigation,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
January 1985, Annals of clinical biochemistry,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
November 1987, Journal of applied physiology (Bethesda, Md. : 1985),
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
January 1999, Neurologia i neurochirurgia polska,
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
January 1994, Alcohol (Fayetteville, N.Y.),
M Luisetti, and E Pozzi, and L Diomede, and M Donnini, and P D Piccioni, and G Bolzoni, and V Peona, and M Salmona
April 1978, Clinica chimica acta; international journal of clinical chemistry,
Copied contents to your clipboard!